PRECIGEN
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
PRECIGEN
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
1998-01-01
Address:
Germantown, Maryland, United States
Country:
United States
Website Url:
http://www.precigen.com
Total Employee:
101+
Status:
Active
Contact:
15409610734
Total Funding:
630.8 M USD
Technology used in webpage:
Domain Not Resolving DNSSEC Microsoft Apple Whitelist ASP.NET 2.0 Klarna
Similar Organizations
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Board_member
2011-11-01
Board_member
2008-01-01
Board_member
2009-03-01
Board_member
2008-02-01
Board_member
2011-11-01
Current Employees Featured
Rutul R. Shah Chief Operating Officer @ Precigen
Chief Operating Officer
2022-01-01
Douglas E. Brough Senior Vice President & Head of Research @ Precigen
Senior Vice President & Head of Research
2020-07-01
Thomas D. Reed Founder & Chief Science Officer, Board of Directors @ Precigen
Founder & Chief Science Officer, Board of Directors
1998-01-01
Hadyn Parry Vice President @ Precigen
Vice President
2018-05-01
Jack Bobo Chief Communications Officer @ Precigen
Chief Communications Officer
2015-07-01
Jeffrey T. Perez Senior Vice President, Intellectual Property Affairs @ Precigen
Senior Vice President, Intellectual Property Affairs
Darryl Webster Senior Vice President, Intellectual Property @ Precigen
Senior Vice President, Intellectual Property
Randal J. Kirk CEO and Chairman @ Precigen
CEO and Chairman
2008-02-01
Samuel Broder Chairman, Health Sector @ Precigen
Chairman, Health Sector
2012-01-01
Phil Tennant Chief Commercial Officer @ Precigen
Chief Commercial Officer
2024-07-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-01-24 | GenVec | GenVec acquired by Precigen | N/A |
| 2016-02-25 | EnviroFlight | EnviroFlight acquired by Precigen | N/A |
| 2015-08-10 | Oxitec | Oxitec acquired by Precigen | 160 M USD |
| 2015-02-13 | ActoGeniX | ActoGeniX acquired by Precigen | 60 M USD |
| 2013-12-20 | Medistem | Medistem acquired by Precigen | N/A |
| 2011-10-24 | Immunologix | Immunologix acquired by Precigen | N/A |
| 2011-02-02 | Agarigen, Inc | Agarigen, Inc acquired by Precigen | N/A |
Investors List
Randal J. Kirk
Randal J. Kirk investment in Series F - Precigen
Third Security
Third Security investment in Series F - Precigen
Randal J. Kirk
Randal J. Kirk investment in Series E - Precigen
NewVa Capital Partners
NewVa Capital Partners investment in Series E - Precigen
Third Security
Third Security investment in Series E - Precigen
Third Security
Third Security investment in Series C - Precigen
NewVa Capital Partners
NewVa Capital Partners investment in Venture Round - Precigen
Third Security
Third Security investment in Series B - Precigen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-12-02 | Histogenics | Precigen investment in Post-IPO Equity - Histogenics | 70 M USD |
Key Employee Changes
Official Site Inspections
http://www.precigen.com Semrush global rank: 4.42 M Semrush visits lastest month: 2.35 K
- Host name: 174.60.185.35.bc.googleusercontent.com
- IP address: 35.185.60.174
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Precigen"
About - Precigen
Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases. Our …See details»
Precigen - Wikipedia
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the functi…See details»
Careers - Precigen
Precigen’s Medical Transparency in Coverage This link leads to the machine-readable files that are made available in response to the federal Transparency …See details»
Maximizing Value for Investors - Precigen
Jan 13, 2025 Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and …See details»
Precigen - Crunchbase Company Profile & Funding
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's …See details»
Precigen - LinkedIn
Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of …See details»
Precigen Reports Full Year 2024 Financial Results and Business …
Aug 28, 2024 Our commercial organization has been working to scale up quickly, right-sizing the organization to rapidly capitalize on the immense demand from patients and treating …See details»
Precigen Reports Full Year 2024 Financial Results and
4 days ago Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using …See details»
Precigen - VentureRadar
" Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and …See details»
Precigen Reports Full Year 2024 Financial Results and Business …
4 days ago Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today …See details»
Precigen Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Precigen has 1 employees across 3 locations and $26.91 m in annual revenue in FY 2022. See insights on Precigen including office locations, competitors, revenue, financials, …See details»
Events & Presentations - Precigen
Jan 16, 2025 Precigen conference call/webcast to discuss full year 2024 financial results and provide business updates. The conference call may be accessed by dialing 1-800-836-8184 …See details»
Investors - Precigen
Advancing Medicine with Precision® Press & Events Stock Financials Governance Resources Nasdaq: PGEN Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage …See details»
Precigen’s SWOT analysis: biotech firm’s stock poised for potential ...
3 days ago In preparation for a potential launch, Precigen has made significant investments in manufacturing capabilities and commercial infrastructure. The company has completed …See details»
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
3 days ago Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ETCompany ParticipantsSteven Harasym - IRHelen Sabzevari - President...See details»
Precigen to Announce Full Year 2024 Financial Results and Provide ...
GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell …See details»
Pipeline - Precigen
PRECIGEN pipeline. Discovery by Design. Our pipeline includes several programs leveraging our technologies in core therapeutic areas of immuno-oncology, autoimmune disorders, and …See details»
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) …
3 days ago The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precigen with a $6.33 average price target, a 274.6% upside from current levels. In a report …See details»
Precigen Reports Full Year 2024 Financial Results and Business …
4 days ago Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using …See details»
Expert Outlook: Precigen Through The Eyes Of 4 Analysts
3 days ago 4 analysts have expressed a variety of opinions on Precigen (NASDAQ:PGEN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below …See details»